Andy Gardiner

Andy has worked for twenty-five years with early-stage biotech companies as CEO, CFO, non-executive director and founder. He has run companies in both crop-protection and plant genetics. He recently took an excursion outside biotech, helping to build digital commerce company.

Andy is a former board member of Swedish animal/human vaccine company Isconova (acquired by Novavax) and CEO of UK plant-genetics start-up Norfolk Plant Sciences. Other previous roles include: Personal Chemistry/Biotage (Swe), InSecta (UK/Spain), Isconova (Swe) and Immudex (DK). He is a co-founder (with Neil) of Double Bioventures. Andy has an MBA from London South Bank University and a BSc in Physics from the University of Manchester.